2021 total revenue was $43.2 million, including product sales of $40.1 million. Core non-COVID-19 product sales increased approximately 13% Y-Y to $33.8 million. 2022 marks the 10th anniversary of CytoSorb® commercialization MONMOUTH JUNCTION, N.J., March 8, 2022 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care […]
Author: Ken Dropiewski
New post-cryptogenic stroke remote telemetry study demonstrates increased atrial fibrillation detection and USD 4 million in cost savings using initial Philips BioTel Heart MCOT monitoring
March 9, 2022 As an initial remote monitoring diagnostic approach, Philips BioTel Heart MCOT detected 4.6 times more patients with atrial fibrillation compared to implantable loop recorder alone Almost eight times lower costs were achieved with improved detection rates and reduction of secondary stroke risk Remote cardiac monitoring via the MCOT […]
Stereotaxis Announces Grand Opening of New Global Headquarters in St. Louis
Company joins Downtown North Urban Insight District in unique mixed-use space to accommodate growing surgical robotics business ST. LOUIS, March 09, 2022 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today is holding the grand opening of its new, 45,000-square-foot global […]
Shockwave Medical Named to Fast Company’s “Most Innovative Company” List
Pioneer of IVL Selected as the Second Most Innovative Medical Device Company SANTA CLARA, Calif., March 08, 2022 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, has been named in Fast Company’s 2022 list of the World’s […]
Dascena Awarded NIH Grant to Reduce Bias in Acute Coronary Syndrome Diagnosis and Treatment
Latest grant is the 9th awarded to Dascena from the National Institute of Health SAN FRANCISCO–(BUSINESS WIRE)–Dascena, a developer of machine learning diagnostic algorithms to enable early disease intervention and improved care outcomes for patients, has received a grant from the National Institute on Minority Health and Health Disparities (part of the National […]
Big Sky Biomedical Appoints Ryan Egeland, M.D., Ph.D., M.B.A., as Managing Director
Dr. Egeland is a Founding Partner of Big Sky Biomedical and will transition from Advisor to Managing Director in his new role. MINNEAPOLIS (PRWEB) MARCH 07, 2022 Big Sky Biomedical, a leading-edge medical device and health technology incubator, announced today that it has appointed Ryan Egeland, M.D., Ph.D., M.B.A., as Managing […]
Eko Named to Fast Company’s Annual List of the World’s 50 Most Innovative Companies for 2022
AI heart and lung disease screening solution top-ranked in the medical devices category, joins the likes of Canva, Microsoft, SpaceX, and more OAKLAND, Calif., March 8, 2022 /PRNewswire/ — Eko, a digital health company advancing heart and lung disease detection, has been named to Fast Company‘s annual list of the World’s Most Innovative Companies for 2022 in […]
SEQUANA MEDICAL SUCCESSFULLY RAISES EUR 28.4 MILLION IN AN EQUITY PLACEMENT
THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 8 March 2022, 7:00 am CET Ghent, Belgium, 8 March 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the […]
InspireMD Reports Fourth Quarter and Year-End 2021 Financial Results
– CGuard™ Revenue Generated 87.5% growth over Q4’20 and 55.9% Year-over-Year –- – Published CGuard Clinical trial results in Journals of the American College of Cardiology – – Established Reimbursement Approval for CGuard from the French National Authority – – CGuard Included as Carotid Stent Treatment Option in National Institute […]
Matinas BioPharma Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
– Fifteen Patients Enrolled to Date in Cohort 4 of EnACT (all oral induction regimen); Topline Interim Data Expected Q3 2022 – – Potential Pathway to NDA Submission for MAT2203 with Confirmatory Data to Come from Cohort 5 of EnACT Trial – – Second in vivo Study of Oral LNC-remdesivir […]



